

Purixan[®] (mercaptopurine) – First-time generic

- On February 27, 2025, <u>Hikma launched</u> an <u>AB-rated</u> generic version of Nova Laboratories' <u>Purixan (mercaptopurine)</u> oral suspension.
 - The FDA granted Competitive Generic Therapy (CGT) designation with 180 days of exclusivity to Hikma for generic Purixan.
- Purixan is approved for the treatment of patients with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen.
- Mercaptopurine is also available as a generic <u>tablet</u> carrying the same indication as Purixan.
- According to IQVIA[™], Purixan had U.S. sales of approximately \$14 million in the 12 months ending December 2024.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.